Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Mirang Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3171-2540; OpenAlex author ID A5062521637. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 5 papers · 2024: 8 papers · 2025: 2 papers · 2026: 1 paper

Papers 20

  1. Clinical Utility of Circulating Tumor DNA Analysis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/11795549261480247↗
  2. Prognostic implications of resection margin status in distal pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.04.001↗
  3. Applicability of current nodal staging system for resected pancreatic cancer after neoadjuvant therapy: a retrospective study. Co-author DOI 10.1016/j.hpb.2025.04.011↗
  4. Re-evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer. Co-author DOI 10.1002/jhbp.12048↗
  5. Efficacy of local treatment for isolated liver metastasis after pancreatectomy in pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1002/jhbp.1352↗
  6. Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant… First author DOI 10.1016/j.hpb.2023.11.015↗
  7. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000001184↗
  8. Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond … Co-author DOI 10.1097/js9.0000000000002034↗
  9. Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer. Co-author DOI 10.1186/s12885-024-12795-5↗
  10. In Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Ductal Adenocarcinoma, Which Response is the More Reliable Indicator for Prognosis, Radiologic or Biochem… Co-author DOI 10.1245/s10434-023-14532-x↗
  11. Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.3390/biomedicines13010062↗
  12. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  13. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels. First author DOI 10.1002/jhbp.1302↗
  14. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score… Co-author DOI 10.1002/jhbp.1313↗
  15. Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer… Co-author DOI 10.1007/s11605-023-05850-2↗
  16. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  17. The incidence and clinical features of familial pancreatic cancer in Korea. Co-author DOI 10.1002/jhbp.1117↗
  18. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Co-author DOI 10.3390/cancers14092067↗
  19. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers14184360↗
  20. The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer. Co-author DOI 10.3390/cancers12082036↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Young Jang · 18 shared papers, 2020–2025 · strength 3.47
  2. Wooil Kwon · 18 shared papers, 2020–2025 · strength 3.47
  3. Won‐Gun Yun · 13 shared papers, 2022–2025 · strength 2.70
  4. Hye‐Sol Jung · 12 shared papers, 2022–2025 · strength 2.55
  5. Michael D. Kluger · 4 shared papers, 2022–2024 · strength 0.73
  6. Alexander S. Thomas · 4 shared papers, 2022–2024 · strength 0.73
  7. Yoon Soo Chae · 3 shared papers, 2024 · strength 0.64
  8. Hyeong Seok Kim · 4 shared papers, 2022–2023 · strength 0.63
  9. Jae Seung Kang · 4 shared papers, 2020–2023 · strength 0.62
  10. Hongbeom Kim · 4 shared papers, 2020–2023 · strength 0.60
  11. Dae Wook Hwang · 2 shared papers, 2025–2026 · strength 0.55
  12. Joon Seong Park · 2 shared papers, 2024 · strength 0.43
  13. Dong Ho Lee · 2 shared papers, 2023–2024 · strength 0.41
  14. Eunsung Jun · 1 shared paper, 2026 · strength 0.32
  15. Sung‐Min Chun · 1 shared paper, 2026 · strength 0.32
  16. Go‐Won Choi · 1 shared paper, 2025 · strength 0.27
  17. Yoonhyeong Byun · 2 shared papers, 2020–2022 · strength 0.26
  18. Ki Byung Song · 1 shared paper, 2025 · strength 0.24
  19. Yejong Park · 1 shared paper, 2025 · strength 0.24
  20. Min Kyu Sung · 1 shared paper, 2025 · strength 0.24
  21. Woohyung Lee · 1 shared paper, 2025 · strength 0.24
  22. Song Cheol Kim · 1 shared paper, 2025 · strength 0.24
  23. Hyung Sun Kim · 1 shared paper, 2024 · strength 0.22
  24. Seulah Park · 1 shared paper, 2024 · strength 0.22
  25. Young‐Jae Cho · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.